Ascletis Pharma announced new data presentations at the 33rd European Congress on Obesity, highlighting their obesity drug candidates. ASC47 combined with semaglutide showed up to 111.8% greater weight loss compared to semaglutide alone. ASC36 demonstrated a much longer half-life and superior weight loss effects in preclinical models compared to existing treatments. These advancements suggest potential new effective therapies for obesity management, with further clinical development anticipated.
Confo Therapeutics announced encouraging preclinical data for CFTX-2034, a novel antibody targeting post-bariatric hypoglycemia (PBH), a condition with no approved treatments. The data showed CFTX-2034 effectively controls insulin and GLP-1 secretion...
Pardee Resources Company announced an agreement to sell about 2,465 acres of surface and mineral property in West Virginia for approximately $57 million, priced at $23,000 per acre. The sale depends on certain contingencies and normal closing conditi...
Western Digital's stock surged to a new 52-week high following a bullish upgrade by Morgan Stanley analyst Erik Woodring, who raised his price target from $488 to $650. The optimism is driven by expected 30%+ year-over-year growth in nearline enterpr...
Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
